Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis study highlights new drug target for malaria

Novartis study highlights new drug target for malaria

2nd December 2013

Novartis has published a new study that has highlighted a potentially promising drug target for the deadly tropical disease malaria.

Published in the journal Nature, the study identifies phosphatidylinositol-4 kinase as a target for an experimental antimalarial compound class called imidazopyrazine. This new type of therapy is capable of inhibiting the development of multiple malaria-causing Plasmodium species.

Its method of action means it could be used to prevent, block and treat multiple stages of the malaria life cycle, making it a potentially potent weapon for use in worldwide efforts to eradicate the disease.

Each year, the condition kills more than 660,000 people, the majority of whom are African children. 

Thierry Diagana, head of the Novartis Institute for Tropical Diseases, said: "This new target for malaria provides an avenue to develop the next-generation antimalarial drugs that are capable of preventing, treating and blocking the spread of malaria, a key goal of Novartis."

This comes after the company received a global corporate citizenship award from the charitable organisation Malaria No More last month, thanks to its contributions to malaria control and elimination.ADNFCR-8000103-ID-801667475-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.